Physician

Larry Lynn Frase, M.D.

According to 2025 Medicare claims, Larry Frase, M.D. (NPI: 1942242995) practices medical oncology in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 75601-4756.

Frase's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 500 traditional Medicare patients, billed 101,924 HCPCS/CPT codes, and received $1,882,724 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,979 prescription claims across 311 beneficiaries totaling $1,815,446 in drug costs, led by Revlimid (Lenalidomide). DME data shows 43 claims. Open Payments data shows 60 records totaling $2,067. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,456,024 and ending at $1,882,724. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,820 to $2,026.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	536	75,357	$1,456,024
2016	772	90,923	$1,540,350
2017	827	86,014	$1,464,358
2018	589	38,220	$692,663
2019	484	12,382	$337,761
2020	532	50,480	$1,208,370
2021	487	91,292	$1,475,512
2022	553	79,803	$1,393,114
2023	601	128,363	$2,418,076
2024	500	101,924	$1,882,724

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	298	3,178	$1,159,165
2016	274	3,128	$1,789,918
2017	293	3,155	$2,280,159
2018	293	2,903	$2,176,026
2019	331	3,206	$2,527,132
2020	376	3,218	$2,901,742
2021	348	3,130	$2,408,955
2022	333	2,949	$2,121,202
2023	329	3,027	$2,151,333
2024	311	2,979	$1,815,446

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	144	$37,649
2016	12	122	$21,699
2017	N/R	63	$8,048
2018	N/R	12	$1,671
2019	N/R	30	$2,583
2020	11	77	$7,990
2021	23	65	$8,709
2022	16	58	$4,363
2023	25	26	$5,307
2024	30	43	$7,236

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	339	1,132	$62
80053	Blood test, comprehensive group of blood chemicals	341	1,352	$10
36415	Insertion of needle into vein for collection of blood sample	341	1,687	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	335	1,396	$8
83615	Lactate dehydrogenase (enzyme) level	182	629	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	16	427	$273,406
Kisqali	Ribociclib Succinate	11	308	$200,375
Eliquis	Apixaban	50	1,925	$37,573
Xarelto	Rivaroxaban	28	1,999	$35,050
Everolimus	Everolimus	14	400	$30,330

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8020	Breast prosthesis, mastectomy form	N	12	14	$4,384
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	18	29	$2,851

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$2,067	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Larry Lynn Frase, M.D.?

Tedicare shows public-source Medicare data for Larry Lynn Frase, M.D. (NPI 1942242995), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Larry Lynn Frase, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Larry Lynn Frase, M.D.?

Larry Lynn Frase, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Larry Lynn Frase, M.D. have Open Payments data?

Larry Lynn Frase, M.D. has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.